Aurora Cannabis (TSX:ACB) revealed its Q4 and 2018 fiscal year results on Monday (September 24), giving investors a closer look at its revenues and upcoming plans to list in the US.

Aurora reported a growth in revenue for the quarter, representing a 223 percent improvement over the same time period last year. The cannabis producer generated C$19.1 million in revenue during Q4.


According to the company, this uptick in revenue was due to a “higher average selling price, per gram of dried cannabis, coupled with a higher proportion of cannabis oil sales.”

The company also indicated in its financials that it expects to produce 150,000 kilograms of cannabis per year at the end of Q2 2019, once all of its licensed facilities are at full capacity.

As part of its expansion, the company secured a C$200 million debt facility with the Bank of Montreal (TSE:BMO) in September. At the end of the quarter the producer held an C$89 million cash position.

US listing will offer new investors chance for cannabis exposure

In its report, the company confirmed a premier US exchange listing is coming. Aurora CEO, Terry Booth, said the listing would give access to a “broader investor audience” the opportunity to participate in the company.

The company will file a registration form with the US Securities and Exchange Commission (SEC) and will seek, pending approval, its proper US exchange.

The company would be joining Canopy Growth (NYSE:CGC,TSX:WEED), Tilray (NASDAQ:TLRY), and Cronos Group (NASDAQ:CRON,TSX:CRON) as Canadian cannabis licensed producers listed across these US exchanges.

Aurora’s pending US listing will arrive following the company’s decision to spin off a separate entity, Australis Capital (CSE:AUSA), which is set to pursue opportunities in the US multistate operator business model.

Australis made its public debut on the Canadian Securities Exchange (CSE) on September 19. Aurora shareholders obtained a stake in the new venture as part of the launch.

During an investor and analyst conference call on Tuesday (September 25), management of the company was asked whether this upcoming US listing will affect the potential for the company to find an established partner outside of cannabis.

Aurora was at the center of rumors of The Coca-Cola Company (NYSE:KO) potentially entering the cannabis space through a partnership looking to develop infused wellness beverages.

Management of the producer was also asked whether the company is inclined to look for a deal in which it retains control or find a partner to take over.

Booth said while it is exciting to see the entry of large companies with no relation to cannabis, Aurora is not “in the mood to be selling out anytime soon.”

“When you start to see the revenues that this company is going to generate on a global basis, then you will see even more attraction coming from these larger companies,” Booth said.

Cam Battley, chief corporate office for Aurora, added the company is well positioned for a deal but is also holding reservation on the type of deal it makes.

In terms of the US listing moving the needle for a potential deal with an established player, Battley said the new investing option “won’t affect things immediately.” Rather, Battley said, it is seen as a move to allow the entry of more investors.

Investor takeaway

Stock for Aurora quickly increased in value during Tuesday’s early trading session. The company rose to a share price of C$12.92, indicating a 5.30 percent increase, as of 1:25 p.m. EST.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 
  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less